Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial

Am J Gastroenterol. 2021 Nov 1;116(11):2292-2295. doi: 10.14309/ajg.0000000000001488.

Abstract

Introduction: Patients with decompensated cirrhosis and hyponatremia have a poor prognosis. We investigated Albumin to Prevent Infection in Chronic Liver Failure trial data to determine whether targeted albumin infusions improved outcome in patients with hyponatremia at baseline.

Methods: We examined the interaction between targeted albumin and standard care for the composite primary end point, stratifying by baseline sodium ≥ and <130 mmol/L.

Results: Randomization to albumin was associated with a significant increase in sodium; however, there was no interaction between sodium category and treatment for the trial primary end point.

Discussion: Targeted intravenous albumin infusions increased serum sodium level in hospitalized hyponatremic patients with cirrhosis, but this did not improve outcome.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albumins / administration & dosage*
  • Hospitalization
  • Humans
  • Hyponatremia / complications*
  • Hyponatremia / drug therapy*
  • Infusions, Intravenous
  • Liver Cirrhosis / complications*
  • Time Factors
  • Treatment Outcome

Substances

  • Albumins

Associated data

  • EudraCT/2014-002300-24
  • ISRCTN/ISRCTN14174793